Pancreatic cancer by Funel, N. (Niccola) et al.
Editorial
Pancreatic Cancer
Niccola Funel,1 Marco Del Chiaro,2 Djuna L. Cahen,3 and Johanna Laukkarinen4
1Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56124 Pisa, Italy
2Pancreatic Surgery Unit, Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC),
Karolinska Institutet, Center for Digestive Diseases, Karolinska University Hospital, K53, 14186 Stockholm, Sweden
3Department of Gastroenterology and Hepatology, Erasmus University Medical Center’s, Gravendijkwal 230, P.O. Box 2040,
3000 CA Rotterdam, Netherlands
4Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Teiskontie 35, P.O. Box 2000,
33521 Tampere, Finland
Correspondence should be addressed to Niccola Funel; niccola.funel@gmail.com
Received 30 December 2014; Accepted 30 December 2014
Copyright © 2015 Niccola Funel et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pancreatic tumors are challenging diseases. Pancreatic ade-
nocarcinoma (PDAC), in particular, is associated with sig-
nificant morbidity and mortality. Another group of exocrine
tumors, intraductal papillary mucinous neoplasia (IPMNs),
represents the paradigm of progression of malignancy and
their connection and differentiation with respect to pancre-
atic ductal adenocarcinoma (PDAC) which is still compli-
cated. In this special issue, we would like to offer readers
an overview of some important aspects for the two most
representative exocrine tumors as IPMN and PDAC. The
original communications within this special issue fall into
four different categories: pancreatic surgery, management of
IPMN patients, treatment of pancreatic tumors, and, last but
not least, some important aspects of basic science in PDAC.
Surgery. Curative resection is considered the only potential
for cure in pancreatic cancer. Complete macroscopic tumor
resection is perhaps the most relevant predictor of long-term
survival in PDAC. Locally advanced pancreatic tumors can
involve vascular structures and adjacent organs, and thus vein
resections and even resections of additional organs may be
needed to achieve the goal. Improving surgical methods to
achieve this goal is crucial in the treatment of this disease.
In pancreatic surgery, postoperative pancreatic fistula
(POPF) remains the most challenging complication after re-
sections, whether pancreatoduodenectomy or distal. POPFs
are contributing significantly to prolonged hospitalization
and mortality. Several studies using various anastomotic
and sealing techniques have been studied to reduce the
amount of POPFs. Some previous investigations have shown
that pancreatic trauma and the following inflammation are
preceding postoperative complications and they should be
avoided. Patients with normal, acinar-cell rich pancreas are
in higher risk to develop POPF. One promising technique
for pancreatoduodenectomy is the Finnish binding pan-
creaticojejunal anastomosis (FBPJ), where the pancreatic
trauma is minimized by avoiding sutures running through
the pancreatic tissue. The preliminary previous studies with
this technique have shown reduced amount of POPF after
pancreatoduodenectomy.
IPMN Management. Intraductal papillary mucinous neo-
plasms of the pancreas (IPMNs) are a high prevalence neo-
plasm of the pancreas. IPMNs can progress from adenoma
to invasive cancer through a process very similar to the one
of the colonic polyps. At the moment the management of
pancreatic IPMN is suggested by the Guidelines of the Inter-
national Association of Pancreatology and by the European
Guidelines for Cystic Tumors of the Pancreas. However, till
now, the available evidence about the diagnosis and treatment
of those tumors is quite low and the clinical decisions are
made on the basis of expert consensus (more than guidelines)
and local expertise. Even though IPMNs represent in one
side an opportunity to prevent pancreas cancer (through
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an early detection and treatment of precancerous lesions),
considering the high risk associated with pancreatic surgery,
there is a potential risk to overtreat patients that might never
develop cancer. Even the decision making in the intraoper-
ative management of IPMNs is complicated: the extent of
resection, the role of parenchyma sparing procedure, and the
role and significance of margins analysis are argument under
investigations and have not been yet defined.
To make the overall picture even more complicated, the
accuracy of the current imaging modalities is reported very
low even in high volume centers. In a recent series the
overall accuracy in defining preoperative diagnosis in cystic
tumors of the pancreas was inferior to 70% and even the
use of endoscopic ultrasound plus FNA was not able to
increase the results. More large studies are needed in order
to better understand the natural history of these tumors, to
discriminate the ones that can progress to cancer from the
ones with low aggressive behavior. At the same time, new
insight into the field of diagnostic is necessary in order to
increase the accuracy of imaging modalities. For the reasons
mentioned above and for the tremendously high prevalence,
IPMNs represent today maybe the most challenging area of
interest in pancreatology, a great opportunity to reduce the
pancreas cancermortality, but also one of themost dangerous
clinical areas.
Pancreatic Cancer Treatments. Pancreatic adenocarcinoma is
one of themost deadly cancers, with an overall 5-year survival
of 5%. Complete surgical resection provides the only chance
for cure. Unfortunately, most patients are diagnosed with
locally advanced or metastatic disease. Chemotherapy, with
and without radiation, has been investigated in both neoad-
juvant and postoperative settings. At present, multimodality
therapy seems to be the future direction. However, the
sequence of surgery, chemotherapy, and radiation remains
to be determined. In the review of this special issue, the
authors examined available data on neoadjuvant treatment in
resectable patients and in patients with borderline resectable
or locally advanced disease.
Of course, the need for new therapies is undisputed.
One of the latest local treatments is high-intensity focused
ultrasound (HIFU), a noninvasive and safe technique to
ablate solid tumors. In this special issue, the authors have
reviewed all 3022 cases, described in the literature, with
respect to safety and efficacy.
Basic Science of PDAC. In the papers published in this special
issue, the authors treated three molecular aspects regarding
the PDAC: indicator tryptase, ATP-binding cassette (ABC)
transporters, and micro-RNA (miRNA) expression. These
molecules are involved in the progression, chemoresistance,
and survival of PDAC patients, respectively. In particular, M.
Ammendola et al. have shown the role of tryptase in PDAC
which is associated with mast cells to increase the microvas-
cular density (MVD) in tissue PDAC. This could play an
important role in vascularization, the absorption of drugs,
and chemoresistance of PDAC. In fact, drug chemoresistance
of PDAC cells is recognized as the primary cause of failure
of chemotherapy. Although biochemical behaviors, including
low drug concentration in the tumor, may contribute to
clinical resistance, different types of molecules, including
ATP-binding cassette transporters, are the main actors in
the extrusion of drugs in different tumors. In particular,
some single nucleotide polymorphisms (SNPs) of the three
most important family genes of ABC (ABCB1, ABCC1, and
ABCG2) are associated with a lower risk of developing pan-
creatic cancer and an increased sensitivity to gemcitabine
than other haplotypes. Finally, the most important epigenetic
factors, such as miRNAs, were confirmed to be “micromole-
cules,” regulating “the great effects.” Their deregulation mod-
ulates several important processes in PDAC, including dif-
ferentiation, tumor progression, and epithelial-mesenchymal
transition (EMT). Nevertheless, miRNAs affect overall sur-
vival and chemoresistance of PDAC patients. Aberrant
expression of three most important miRNAs (miR-21, miR-
155, and miR-101) is strongly associated with PDAC, IPMN,
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